Kathleen Dass, MD
Allergy & Immunology · Oak Park, MINPI 1477849610
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $388,010 of the $446,288 with a category attached, or 86.9%. 32 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.8% of the total. Reporting peaked in 2023 at $152,984 and has fallen 61.9% since, to $58,220 in 2025. Among allergy & immunology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,087 payments — averaging $410.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$133K
- GSK$133K
- AstraZeneca$92K
- Sanofi$48K
- Amgen$14K
- Genentech USA, Inc.$14K
- plus $13K from 26 others
What the payments were for
- Consulting fees$10,5912%
- Speaking & faculty fees$388,01087%
- Travel & lodging$22,8575%
- Food & beverage$24,3765%
- Education$4550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 177 | $133,133 |
| GSK | 213 | $133,044 |
| AstraZeneca | 258 | $91,726 |
| Sanofi | 79 | $47,531 |
| Amgen | 69 | $13,835 |
| Genentech USA, Inc. | 76 | $13,756 |
| Novartis | 42 | $7,345 |
| Teva Pharmaceuticals USA, Inc. | 10 | $1,803 |
| CSL Behring | 45 | $931 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $682 |
| Boehringer Ingelheim | 19 | $436 |
| Pfizer | 10 | $330 |
| Grifols USA, LLC | 7 | $180 |
| Sanofi-aventis U.S. LLC | 3 | $177 |
| Lilly USA, LLC | 10 | $172 |
| Amarin Pharma, Inc. | 3 | $149 |
| Novo Nordisk | 2 | $146 |
| Alk-abello, Inc | 6 | $125 |
| LEO Pharma Inc. | 5 | $111 |
| Galderma Laboratories, L.p. | 4 | $105 |
| Blueprint Medicines Corporation | 3 | $81 |
| Kaleo, Inc. | 3 | $74 |
| Organon | 5 | $74 |
| Pharming Healthcare, Inc. | 3 | $69 |
| Optinose US, Inc. | 2 | $55 |
| Greer Laboratories, Inc. | 2 | $49 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| AbbVie | 2 | $48 |
| Biocryst US Sales Co., LLC | 1 | $27 |
| Phadia US Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$174,670
- NUCALA$80,043
- TEZSPIRE$74,243
- AIRSUPRA$25,696
- XOLAIR$13,001
- AirDuo RespiClick$1,680
- ProAir Digihaler$1,680
- ArmonAir Digihaler$1,680
- TRELEGY ELLIPTA$1,547
- FASENRA$526
- BREZTRI$189
- Rhapsido$135
- JARDIANCE$125
- Haegarda$125
- Ozempic$125
- Vascepa$125
- EUCRISA$125
- CIBINQO$107
How this compares
$446,288 in reported general payments places this provider in the 95th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 312 | $863,614 |
| Dupixent SyringeDupilumab | 138 | $541,986 |
| NucalaMepolizumab | 74 | $315,093 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 352 | $262,274 |
| Dupixent PenDupilumab | 50 | $188,206 |
| FasenraBenralizumab | 27 | $149,224 |
| TezspireTezepelumab-Ekko | 34 | $145,784 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $64,641 |
| Arnuity ElliptaFluticasone Furoate | 56 | $16,407 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,991 |
| Montelukast Sodium | 396 | $6,511 |
| DuleraMometasone/Formoterol | 19 | $6,185 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 171 | $5,559 |
| OdactraMite,d.Farinae-D.Pteronyssinus | 13 | $4,435 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $4,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $133,044 | $604,765501 claims |
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere | $91,726 | $359,650165 claims |
| Alk-abello, IncOdactra | $125 | $4,43513 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $3,04718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Oak Park
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
- Jason ParisLivonia$44K
- Cem AkinNorthville$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.